Cancer cells express high levels of CBS and CTH and their genetic or pharmacological inhibition leads to a reduction in tumor vasculature [125,126,127], suggesting that the TSP metabolic reprogramming may be a promising therapeutic strategy for solid tumors (Table 1). This evidence concerns the gene CBS and neoplasm.